Drug Approval | June 01, 2026
Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial
The therapy also delivered significant improvements in key liver enzyme markers
The therapy also delivered significant improvements in key liver enzyme markers
The approval marks a major milestone in the global fight against antimicrobial resistance
This marks one of the most closely watched oncology readouts at this year’s medical congress
Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The company highlighted continued demand strength and pricing resilience despite global disruptions
Subscribe To Our Newsletter & Stay Updated
